Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Depreciation & Amortization (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 25.0% year-over-year to $600000.0; the TTM value through Dec 2025 reached $600000.0, down 25.0%, while the annual FY2025 figure was $600000.0, 25.0% down from the prior year.
  • Accumulated Depreciation & Amortization hit $600000.0 in Q4 2025 for Phathom Pharmaceuticals, down from $800000.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.3 million in Q3 2022 and bottomed at $100000.0 in Q1 2023.
  • Average Accumulated Depreciation & Amortization over 4 years is $577923.1, with a median of $600000.0 recorded in 2022.
  • Year-over-year, Accumulated Depreciation & Amortization tumbled 92.33% in 2023 and then skyrocketed 500.0% in 2024.
  • Phathom Pharmaceuticals' Accumulated Depreciation & Amortization stood at $600000.0 in 2022, then changed by 0.0% to $600000.0 in 2023, then soared by 33.33% to $800000.0 in 2024, then fell by 25.0% to $600000.0 in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $600000.0, $800000.0, and $600000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.